Clinical and demographic variables of patients with multiple sclerosis and healthy subjects that received COVID-19 vaccination
| Study population | Patients with MS, n=528 | Healthy subjects, n=627 | ||||||
| Cladribine, n=75 | Alemtuzumab, n=34 | Natalizumab, n=37 | S1P-R mod., n=61 | Anti-CD20, n=183 | Other DMT, n=95 | Untreated, n=55 | ||
| Follow-up after second vaccine, days | ||||||||
| Median | 28 | 24 | 33 | 28 | 32 | 36 | 38 | 18 |
| 25–75 IQR | 19 | 28 | 20 | 20 | 21 | 18 | 23 | 14 |
| Gender, n (%) | ||||||||
| Females | 67 (89) | 27 (79) | 31 (84) | 44 (72) | 144 (79) | 72 (76) | 38 (69) | 435 (69) |
| Males | 8 (11) | 7 (21) | 6 (16) | 17 (28) | 39 (21) | 23 (24) | 17 (31) | 192 (31) |
| Age, years | ||||||||
| Median | 46 | 40 | 46 | 50 | 48 | 56 | 58 | 50 |
| 25–75 IQR | 15 | 15 | 18 | 14 | 15 | 15 | 18 | 21 |
| Disease duration, years | ||||||||
| Median | 4 | 11 | 9 | 12 | 6 | 14 | 16 | |
| 25–75 IQR | 10 | 8 | 12 | 7 | 11 | 13 | 17 | |
| Time from last Tx dose to vaccination, months | ||||||||
| Median | 8 | 51 | 2 | 4 | ||||
| 25–75 IQR | 9 | 30 | 3 | 3 | ||||
| Patients with SARS-CoV-2 SPIKE RBD IgG >70 AU | ||||||||
| n, (%) | 69 (92) | 33 (97) | 33 (97) | 11 (18) | 37 (20) | 91 (96) | 53 (96) | 618 (99) |
| SARS-CoV-2 RBD IgG titre | ||||||||
| Median | 217 | 261 | 183 | 5 | 6 | 209 | 187 | 283 |
| 25–75 IQR | 156 | 95 | 119 | 17 | 55 | 102 | 133 | 145 |
DMT, disease-modifying therapies; S1P-R mod., sphingosine-1-phosphate receptor modulator.